• Cycloheximide: Translational Strategies for Targeting Protei

  2026-05-27

  Cycloheximide, a potent protein biosynthesis inhibitor, is central to dissecting protein turnover and cell fate in advanced translational research. This thought-leadership article bridges mechanistic insights with strategic assay guidance, highlighting the compound's role in apoptosis, fibrosis, and disease modeling. By integrating recent findings—including the antifibrotic targeting of USP4 in renal fibrosis—and referencing both APExBIO’s high-purity Cycloheximide and emerging literature, we chart pathways for impactful experimental design and translational discovery.

• Microbiota Interventions and Neuroinflammation in Hepatic En

  2026-05-27

  This study utilized [18F]PBR146 PET imaging to evaluate the efficacy of Bifidobacterium and fecal microbiota transplantation (FMT) in reducing neuroinflammation in a rat model of chronic hepatic encephalopathy (HE). The research revealed that Bifidobacterium, but not FMT, significantly inhibited neuroinflammation in specific brain regions, highlighting the nuanced impact of gut-targeted therapies on the gut–liver–brain axis.

• Single-Base 5hmC Mapping Reveals Context-Dependent Roles in

  2026-05-26

  This study delivers the first single-base resolution map of 5-hydroxymethylcytosine (5hmC) in rice, revealing its dynamic, context-dependent regulatory roles during drought stress adaptation. The findings provide a mechanistic foundation for future research into plant epigenetic responses and the development of resilient crops.

• Alda 1: ALDH2 Activator Workflows for Cardiac and Dermatitis

  2026-05-26

  Alda 1 enables targeted activation of ALDH2, offering double-digit fold enzymatic enhancement even in impaired variants. This article translates the latest mechanistic breakthroughs into actionable protocols for advancing cardiac ischemia and radiation dermatitis research.

• Digestive Transformations of Withania somnifera Bioactives M

  2026-05-25

  This study provides a detailed LC-MS/MS-based analysis of how key Withania somnifera (ashwagandha) bioactives are transformed under simulated digestive conditions, highlighting compound-specific stability and metabolic lability. The findings refine in vitro modeling of botanical pharmacokinetics and inform future preclinical research on complex herbal extracts.

• Bacterial Effector NleE Disrupts ZPR1 Phase Separation to In

  2026-05-25

  Ouyang et al. (2023) uncover a mechanism by which the EPEC effector NleE disrupts the liquid-liquid phase separation (LLPS) of the host zinc finger protein ZPR1, thereby antagonizing the unfolded protein response of the endoplasmic reticulum (UPRER). This work highlights the value of chemical crosslinkers for studying transient protein interactions and provides a foundation for future research on host-pathogen interactions and transcriptional regulation.

• Prevotella copri Depletes IPyA to Accelerate Breast Cancer P

  2026-05-24

  A recent study demonstrates that Prevotella copri, enriched in the gut microbiota of breast cancer patients, accelerates tumor growth by depleting host indole-3-pyruvic acid (IPyA) and inactivating AMPK via UHRF1-mediated mechanisms. These findings clarify a direct microbiota-metabolite-tumor axis and suggest new avenues for targeting breast cancer progression.

• Optimizing mRNA Workflows: Scenario-Driven Guidance with Pse

  2026-05-23

  This article delivers an evidence-based, scenario-driven guide for biomedical researchers seeking to enhance mRNA synthesis, cell assay reproducibility, and immunogenicity profiles using Pseudo-UTP (SKU B7972). Drawing from recent literature and emphasizing real laboratory challenges, we examine how Pseudo-UTP addresses RNA stability, translation efficiency, and product reliability. Practical protocol parameters and vendor selection insights empower bench scientists to make informed, workflow-optimized decisions.

• Applied Workflows with mCherry mRNA: Enhanced Red Fluorescen

  2026-05-22

  EZ Cap™ mCherry mRNA (5mCTP, ψUTP) empowers researchers with robust, immune-evasive red fluorescent protein expression for high-precision live-cell tracking and quantitative reporter assays. Its Cap 1 structure and nucleotide modifications enable reproducible results even in sensitive or immune-competent cell systems. Explore actionable workflows, troubleshooting, and the latest comparative insights for optimal deployment.

• Digestive Metabolomics of Ashwagandha: LC-MS/MS Reveals Key

  2026-05-22

  This study applies advanced LC-MS/MS and metabolomics to map how Withania somnifera (ashwagandha) extracts are chemically transformed under simulated digestive conditions. The research clarifies the stability and biotransformation of major withanolides, informing the development of more predictive in vitro models for botanical pharmacokinetics.

• Cy5 TSA Fluorescence System Kit: Amplify Sensitivity in IHC

  2026-05-21

  The Cy5 TSA Fluorescence System Kit empowers researchers to detect low-abundance targets in immunohistochemistry, immunocytochemistry, and in situ hybridization with up to 100-fold signal amplification. Its rapid, HRP-catalyzed workflow ensures reproducible, high-resolution imaging—enabling breakthrough insights in cancer and cellular biology.

• Z-WEHD-FMK: Illuminating Caspase-1/4/5 Pathways in Pyroptosi

  2026-05-21

  Explore how Z-WEHD-FMK empowers advanced inflammation research by irreversibly inhibiting caspase-1, -4, and -5. This article uniquely bridges molecular assay design with the latest mechanistic insights from HOXC8-caspase regulation, offering next-level guidance for cell biology and infectious disease research.

• Cabozantinib XL184 in RCC: Protocols, Adaptation, and Troubl

  2026-05-20

  Cabozantinib (XL184) enables precise multi-kinase pathway inhibition and phosphoproteomic adaptation analysis in renal cell carcinoma research. This article delivers actionable protocol guidance, troubleshooting strategies, and insights from chronic exposure models, positioning APExBIO’s reagent as a benchmark for reproducible antiangiogenic studies.

• JHU-083: A 6-diazo-5-oxo-L-norleucine Precursor for Glutamin

  2026-05-20

  JHU-083, a 6-diazo-5-oxo-L-norleucine precursor, is a potent and selective glutaminase antagonist with demonstrated utility in glutaminase pathway and neurological disease research. Its specificity for cerebral CD11b cells and robust solubility profile make it a high-value tool for experimental cerebral malaria and glutamate excitotoxicity models. Stringent purity and validated benchmarks support its role in advanced biochemical workflows.

• Actinomycin D: Precision Transcriptional Inhibition in Cance

  2026-05-19

  Actinomycin D (ActD) from APExBIO empowers researchers to dissect RNA stability, transcriptional stress, and apoptosis induction in advanced cancer models. This guide delivers actionable protocols, troubleshooting tips, and cross-study insights for maximizing experimental reliability and translational relevance.

497 records 13/34 page Previous Next First page 上5页 1112131415 下5页 Last page